Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal ...

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully ...

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt ...

Cash and Cash Equivalents: As of March 31, 2025, Kalaris had cash and cash equivalents of $101.0 million, compared with cash and cash equivalents of $1.6 million as of December 31, 2024. The increase ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

LYTENAVA (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in th ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received the approval from the U.S. Food and Drug ...

Rahway, New Jersey Friday, May 16, 2025, 13:00 Hrs [IST] ...